1-6 of 6
Judah Folkman
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Can Angiogenesis Regulatory Proteins Guide Ultra-early Detection and Therapy of Recurrent Human Cancer?

Judah Folkman, Nava Almog, Monica Bertagnollli, Flavia Cassiola, Susan Connors, Lisa Diller, Sean Downing, Joseph Italiano, Marsha Moses, George Naumov, Jon Peterson, Suzanne Shusterman, Taturo Udagawa, Giannoula Klement
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (19_Supplement): PL06-03.
Published: 15 August 2014
View article titled, Can Angiogenesis Regulatory Proteins Guide Ultra-early Detection and Therapy of Recurrent Human Cancer?
Journal Articles

Combined Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor (EGFR) Blockade Inhibits Tumor Growth in Xenograft Models of EGFR Inhibitor Resistance

George N. Naumov, Monique B. Nilsson, Tina Cascone, Alexandra Briggs, Oddbjorn Straume, Lars A. Akslen, Eugene Lifshits, Lauren Averett Byers, Li Xu, Hua-kang Wu, Pasi Jänne, Susumu Kobayashi, Balazs Halmos, Daniel Tenen, Xi M. Tang, Jeffrey Engelman, Beow Yeap, Judah Folkman, Bruce E. Johnson, John V. Heymach
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (10): 3484–3494.
https://doi.org/10.1158/1078-0432.CCR-08-2904
Published: 18 May 2009
View article titled, Combined Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor (EGFR) Blockade Inhibits Tumor Growth in Xenograft Models of EGFR Inhibitor Resistance
Open the PDF for Combined Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor (EGFR) Blockade Inhibits Tumor Growth in Xenograft Models of EGFR Inhibitor Resistance in another window
Journal Articles

Linking Antibody Fc Domain to Endostatin Significantly Improves Endostatin Half-life and Efficacy

Tong-Young Lee, Robert M. Tjin Tham Sjin, Shahla Movahedi, Bissan Ahmed, Elke A. Pravda, Kin-Ming Lo, Stephen D. Gillies, Judah Folkman, Kashi Javaherian
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (5): 1487–1493.
https://doi.org/10.1158/1078-0432.CCR-07-1530
Published: 03 March 2008
View article titled, Linking Antibody Fc Domain to Endostatin Significantly Improves Endostatin Half-life and Efficacy
Open the PDF for Linking Antibody Fc Domain to Endostatin Significantly Improves Endostatin Half-life and Efficacy in another window
Journal Articles

Blood-Based Biomarkers of SU11248 Activity and Clinical Outcome in Patients with Metastatic Imatinib-Resistant Gastrointestinal Stromal Tumor

Anat Norden-Zfoni, Jayesh Desai, Judith Manola, Paul Beaudry, Jeremy Force, Robert Maki, Judah Folkman, Carlo Bello, Charles Baum, Sam E. DePrimo, David R. Shalinsky, Goerge D. Demetri, John V. Heymach
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (9): 2643–2650.
https://doi.org/10.1158/1078-0432.CCR-06-0919
Published: 01 May 2007
View article titled, Blood-Based Biomarkers of SU11248 Activity and Clinical Outcome in Patients with Metastatic Imatinib-Resistant Gastrointestinal Stromal Tumor
Open the PDF for Blood-Based Biomarkers of SU11248 Activity and Clinical Outcome in Patients with Metastatic Imatinib-Resistant Gastrointestinal Stromal Tumor in another window
Journal Articles

Differential Effects of Vascular Endothelial Growth Factor Receptor-2 Inhibitor ZD6474 on Circulating Endothelial Progenitors and Mature Circulating Endothelial Cells: Implications for Use as a Surrogate Marker of Antiangiogenic Activity

Paul Beaudry, Jeremy Force, George N. Naumov, Andrew Wang, Cheryl H. Baker, Anderson Ryan, Shay Soker, Bruce E. Johnson, Judah Folkman, John V. Heymach
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (9): 3514–3522.
https://doi.org/10.1158/1078-0432.CCR-04-2271
Published: 02 May 2005
View article titled, Differential Effects of Vascular Endothelial Growth Factor Receptor-2 Inhibitor ZD6474 on Circulating Endothelial Progenitors and Mature Circulating Endothelial Cells: Implications for Use as a Surrogate Marker of Antiangiogenic Activity
Open the PDF for Differential Effects of Vascular Endothelial Growth Factor Receptor-2 Inhibitor ZD6474 on Circulating Endothelial Progenitors and Mature Circulating Endothelial Cells: Implications for Use as a Surrogate Marker of Antiangiogenic Activity in another window
Journal Articles

Phase II Study of the Antiangiogenic Agent SU5416 in Patients with Advanced Soft Tissue Sarcomas

John V. Heymach, Jayesh Desai, Judith Manola, Darren W. Davis, David J. McConkey, David Harmon, David P. Ryan, Geraldine Goss, Travis Quigley, Annick D. Van den Abbeele, Stuart G. Silverman, Susan Connors, Judah Folkman, Christopher D. M. Fletcher, George D. Demetri
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (17): 5732–5740.
https://doi.org/10.1158/1078-0432.CCR-04-0157
Published: 08 September 2004
View article titled, Phase II Study of the Antiangiogenic Agent SU5416 in Patients with Advanced Soft Tissue Sarcomas
Open the PDF for Phase II Study of the Antiangiogenic Agent SU5416 in Patients with Advanced Soft Tissue Sarcomas in another window